BRK-B vs JCAP
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
JCAP presents a stark contrast between deep fundamental value and alarming insider behavior. While the Piotroski F-Score of 4/9 indicates stable health and the stock trades at a significant discount to its Graham Number ($32.19) and Intrinsic Value ($39.48), the technical trend is completely bearish. The company boasts an exceptional ROE of 43.78% and a very low P/E of 3.55, but these are overshadowed by massive insider selling totaling over $223M. Consequently, the valuation appeal is tempered by a lack of internal confidence and poor earnings surprise history.
Compare Another Pair
Related Comparisons
BRK-B vs JCAP: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Jefferson Capital, Inc. (JCAP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.